Daniel E Forman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Daniel E Forman has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Cittadini
Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy
1 shared publication Gohar Azhar
1 shared publicationJ Y Wei
1 shared publication- Jeanne Y. Wei
Department of Geriatrics, Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
1 shared publication Pamela S Douglas
1 shared publication
Latest Publications
- 1 July 1993
- Vol. 48 (7) , 32-8, 43
MI: making therapeutic choices when the options are unclear.
Aged adults are particularly susceptible to cardiac disease, with a high incidence of myocardial infarction (MI) and MI-related mortality. How to treat them is not completely understood, because the major therapeutic trials for MI have studied predominantly younger adults. Moreover, these trials have tended to exclude women and patients with comorbidities, characteristics that are more typical of older cardiac patients. Therefore, whether these trials can be applied to our aged MI patients is unclear. This review analyzes data from earlier trials to better delineate their implications for the elderly MI patients that we frequently treat.
- 1 July 1993
- Vol. 48 (7) , 32-8, 43
MI: making therapeutic choices when the options are unclear.
Aged adults are particularly susceptible to cardiac disease, with a high incidence of myocardial infarction (MI) and MI-related mortality. How to treat them is not completely understood, because the major therapeutic trials for MI have studied predominantly younger adults. Moreover, these trials have tended to exclude women and patients with comorbidities, characteristics that are more typical of older cardiac patients. Therefore, whether these trials can be applied to our aged MI patients is unclear. This review analyzes data from earlier trials to better delineate their implications for the elderly MI patients that we frequently treat.